TRUPCR Europe, a global leader in molecular diagnostics, today announces the launch of its first kit within its NGS range, truNGS©.
The comprehensive Solid Tumour Panel kit is designed to detect SNVs, Indels, CNVs, and RNA fusions in 35 markers along with hotspots in 6 PGx genes. The kit targets lung, gastro-intestinal/colorectal, breast, liver and ovarian solid tumours. The library prep and target enrichment reagents included in the kit allow for comprehensive exon coverage, using hybrid capture technology. The kit range has been designed in line with NCCN and ESMO guidelines to streamline the workflow and provide exceptional exon coverage for clinically significant gene targets.
The truNGS range will complement the already established TRUPCR molecular diagnostic qPCR kits, which boasts one of the largest group of CE-IVD qPCR oncology kits on the market. With a pipeline of oncology NGS panel kits currently in development, further kits will be added to the truNGS range early next year.
Harminder Singh, Director of TRUPCR Europe said:
We are delighted to announce the launch of our first NGS Panel kit allowing TRUPCR Europe to offer our customers a complete range of MDx solutions helping them increase efficiencies in the lab, ultimately leading to better patient care.
For more information, please follow the link to our truNGS© Solid Tumour NGS kit flyer.
